Orthofix Medical (OFIX) 10-Q/A 24 Mar 14 2013 Q1 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	Mar. 14, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q/A	'
Amendment Flag	'true	'
Amendment Description	'Orthofix International N.V. (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2013, which was originally filed on May 9, 2013 (the “Form 10-Q”), to restate certain financial information for the three months ended March 31, 2013and 2012 due to errors in the Company’s accounting for revenue recognition. Details on the restatement and its impact on the Company’s control and procedures are included in Part I, Item 1. Financial Statements, under “Note 2 - Restatement of the Condensed Consolidated Financial Statements” and Part I, Item 4. Controls and Procedures, respectively. For convenience of the reader, this Amendment No. 1 sets forth the Form 10-Q in its entirety, as modified and superseded where necessary to reflect the restatement. The following items have been amended principally as a result of and to reflect the restatement: • Part I - Item 1. Financial statements; (See Note 2) • Part I - Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations; • Part I - Item 4. Controls and Procedures; and • Part II - Item 6. Exhibits This Amendment No. 1 amends only the portions of the Form 10-Q listed in the sections noted above. This Amendment No. 1 does not reflect events occurring after the original filing date of the Form 10-Q other than those associated with the restatement.	'
Document Period End Date	31-Mar-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'OFIX	'
Entity Registrant Name	'ORTHOFIX INTERNATIONAL N V	'
Entity Central Index Key	'0000884624	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	18,187,194

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2013		Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets:	'		'	'	'
Cash and cash equivalents	$33,675	[1]	$31,055	$47,053	$33,207
Restricted cash	29,446	[1]	21,314	'	'
Trade accounts receivable, less allowances of $11,731 and $13,543 at March 31, 2013 and December 31, 2012, respectively	96,506	[1]	107,312	'	'
Inventories	84,691	[1]	83,373	'	'
Deferred income taxes	33,915	[1]	33,450	'	'
Prepaid expenses and other current assets	34,390	[1]	34,079	'	'
Total current assets	312,623	[1]	310,583	'	'
Property, plant and equipment, net	54,119	[1]	53,835	'	'
Patents and other intangible assets, net	6,935	[1]	7,290	'	'
Goodwill	72,607	[1]	74,388	'	'
Deferred income taxes	19,176	[1]	18,881	'	'
Other long-term assets	10,298	[1]	7,920	'	'
Total assets	475,758	[1]	472,897	'	'
Current liabilities:	'		'	'	'
Trade accounts payable	14,987	[1]	22,575	'	'
Other current liabilities	44,729	[1]	39,610	'	'
Total current liabilities	59,716	[1]	62,185	'	'
Long-term debt	20,000	[1]	20,000	'	'
Deferred income taxes	12,225	[1]	11,456	'	'
Other long-term liabilities	10,425	[1]	11,424	'	'
Total liabilities	102,366	[1]	105,065	'	'
Contingencies (Note 17)	'	[1]	'	'	'
Shareholders' equity:	'		'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,453,294 and 19,339,329 issued and outstanding as of March 31, 2013 and December 31, 2012, respectively	1,945	[1]	1,934	'	'
Additional paid-in capital	250,381	[1]	246,306	'	'
Retained earnings	119,347	[1]	114,847	'	'
Accumulated other comprehensive income	1,719	[1]	4,745	'	'
Total shareholders' equity	373,392	[1]	367,832	'	'
Total liabilities and shareholders' equity	$475,758	[1]	$472,897	'	'
[1]	Unaudited

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013		Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'		'
Trade accounts receivable, allowances	$11,731	[1]	$13,543
Common shares, par value	$0.10	[1]	$0.10
Common shares, authorized	50,000,000	[1]	50,000,000
Common shares, issued	19,453,294	[1]	19,339,329
Common shares, outstanding	19,453,294	[1]	19,339,329
[1]	Unaudited

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Income Statement [Abstract]	'	'
Product sales	$91,336	$97,608
Marketing service fees	12,037	11,328
Net sales	103,373	108,936
Cost of sales	25,617	21,378
Gross profit	77,756	87,558
Operating expenses	'	'
Sales and marketing	45,054	47,128
General and administrative	18,330	14,570
Research and development	5,741	7,050
Amortization of intangible assets	544	580
Charges related to US Government Resolutions	'	310
Total operating expenses	69,669	69,638
Operating income	8,087	17,920
Other income and expense	'	'
Interest expense, net	-560	-2,221
Other income (expense)	4,764	-631
Total other income (expense)	4,204	-2,852
Income before income taxes	12,291	15,068
Income tax expense	-4,681	-6,471
Net income from continuing operations, net of tax	7,610	8,597
Discontinued operations (Note 16)	'	'
(Loss) income from discontinued operations	-4,434	527
Income tax benefit	1,324	283
Net (loss) income from discontinued operations, net of tax	-3,110	810
Net income	4,500	9,407
Net income per common share- basic:	'	'
Net income from continuing operations, net of tax	$0.39	$0.46
(loss) income from discontinued operations, net of tax	($0.16)	$0.04
Net income per common share- basic	$0.23	$0.50
Net income per common share- diluted:	'	'
Net income from continuing operations, net of tax	$0.39	$0.45
(loss) income from discontinued operations, net of tax	($0.16)	$0.04
Net income per common share- diluted	$0.23	$0.49
Weighted average number of common shares:	'	'
Basic	19,431,093	18,675,694
Diluted	19,691,141	19,116,195
Comprehensive income	$1,474	$11,808

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013		Mar. 31, 2012
Cash flows from operating activities:	'		'
Net income	$4,500		$9,407
Adjustments to reconcile net income to net cash provided by operating activities:	'		'
Depreciation and amortization	5,029		5,717
Amortization of debt costs	180		296
Provision for doubtful accounts	1,374		3,222
Deferred income taxes	-6		-2,652
Share-based compensation	1,943		1,433
Excess income tax benefit on employee stock-based awards	-78		'
Income tax benefit on employee stock-based awards	563		-389
Other	391		-1,776
Change in operating assets and liabilities:	'		'
Trade accounts receivable	8,589		-5,423
Inventories	-2,100		-1,510
Escrow receivable	'		41,537
Prepaid expenses and other current assets	2,695		8,711
Trade accounts payable	-7,247		-4,041
Other current liabilities	2,070		-5,544
Long-term assets	-1,805		-21
Long-term liabilities	-1,039		'
Net cash provided by operating activities	15,059		48,967
Cash flows from investing activities:	'		'
Capital expenditures for property, plant and equipment	-6,029		-6,372
Capital expenditures for intangible assets	-44		-151
Net cash used in investing activities	-6,073		-6,523
Cash flows from financing activities:	'		'
Net proceeds from issuance of common shares	2,143		6,641
Repayments of long-term debt	'		-3,750
(Repayment of) proceeds from bank borrowings, net	-15		69
Changes in restricted cash	-8,141		-32,271
Excess income tax benefit on employee stock-based awards	78		389
Net cash used in financing activities	-5,935		-28,922
Effect of exchange rate changes on cash	-431		324
Net increase in cash and cash equivalents	2,620		13,846
Cash and cash equivalents at the beginning of the period	31,055		33,207
Cash and cash equivalents at the end of the period	$33,675	[1]	$47,053
[1]	Unaudited

Summary_of_significant_account

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2013
Accounting Policies [Abstract]	'
Summary of significant accounting policies	'
	1. Summary of significant accounting policies
	(a) Basis of presentation
	The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S., have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto of the 2012 Form 10-K/A. The notes to the unaudited condensed consolidated financial statements are presented on a continuing operations basis unless otherwise noted.
	(b) Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net income or shareholders’ equity.
	(c) Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to the resolution of U.S. government matters, contractual allowances, doubtful accounts, inventories, taxes, shared-based compensation, and potential goodwill and intangible asset impairment. Actual results could differ from these estimates.
	(d) Foreign Currency Translation
	The financial statements for operations outside the United States are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at year end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity.

Restatement_of_the_Condensed_C

Restatement of the Condensed Consolidated Financial Statements	3 Months Ended
	Mar. 31, 2013
Text Block [Abstract]	'
Restatement of the Condensed Consolidated Financial Statements	'
	2. Restatement of the Condensed Consolidated Financial Statements
	Background
	In July 2013, the Audit Committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) commenced an independent review with the assistance of outside professionals into whether the Company had properly recognized revenue under U.S. generally accepted accounting principles (“GAAP”) in connection with certain revenue that had been recorded in 2012 and 2011 (the “Independent Review”). In conjunction with the Independent Review, the Company concluded that material errors existed in the previously issued financial statements for the fiscal years ended December 31, 2012, 2011 and 2010 (as well as the interim quarterly periods within such years), as well as for the interim quarterly period ended March 31, 2013. In addition, the Company has identified and corrected errors occurring prior to January 1, 2010 by recognizing a cumulative adjustment to beginning retained earnings in the consolidated statements of changes in shareholders’ equity included in the consolidated financial statements filed with the 2012 Form 10-K/A.
	In reaching these conclusions, the Company considered information obtained in the Independent Review, including emails, data and interviews with current and former employees that indicated (i) the existence of extra-contractual terms or arrangements at the onset of the sale and concessions agreed to subsequent to the initial sale, such as extended payment terms, and return and exchange rights for sales to distributors with respect to certain transactions, (ii) that at the time of some sales collection was not reasonably assured, and (iii) that certain amounts previously characterized as commissions were paid to related parties of the applicable customer.
	The Company assessed the information derived from the Independent Review in making determinations with respect to accounting adjustments reflected in the restated consolidated financial statements contained in this Form 10-Q/A and in the 2012 Form 10-K/A, and such determinations are consistent with the findings of the Independent Review. In addition to the matters that were the subject of the Independent Review, certain other adjustments identified by management, including revisions to inventory reserves and royalties, were made to the consolidated financial statements in connection with the restatement.
	The correction of these errors had the following impact for the three months ended March 31, 2013 and March 31, 2012: increased net sales by $3.1 million and decreased net sales by $7.1 million, respectively; and increased net income from continuing operations by $2.7 million and decreased net income from continuing operations by $3.6 million, respectively. The following include descriptions of the significant adjustments to the Company’s financial position and results of operations from the previously reported consolidated financial statements.
	Distributor Revenue Recognition
	The Company has determined that it previously recognized revenue with respect to certain distributor relationships before all revenue recognition criteria were met. Specifically, the Company has determined that a fixed or determinable sales price did not exist, and/or collection was not reasonably assured, with respect to certain transactions where revenue had previously been recognized at the time of shipment. Specifically, the Company’s review revealed arrangements, or extra-contractual terms, with certain of the Company’s distributors regarding extended payment terms, return or exchange rights, and contingent payment obligations for sales to such distributors with respect to certain transactions. There were also concessions being made subsequent to the shipment of inventory to the distributors and the related revenue recognition. Based on the results of this review, it was determined that these arrangements were not appropriately evaluated under the appropriate revenue recognition criteria applicable under GAAP.
	The Company previously recognized distributor revenue as title and risk of loss passed at either shipment from the Company’s facilities or receipt at the distributor’s facility, assuming all other revenue recognition criteria had been achieved (the “sell-in method”). Based on review of all facts and circumstances related to the arrangements described above, the Company determined that in many instances the revenue recognition criteria under the sell-in method were not satisfied at the time of shipment or receipt; specifically, the existence of extra-contractual terms or arrangements caused the Company not to meet the fixed or determinable criteria for revenue recognition in some cases, and in others collectability had not been established. In situations where the Company is unable to reasonably estimate the effects of these extra-contractual terms, it is precluded from recognizing revenue relating to distributor arrangements until the product is delivered to the end customer. This method is commonly referred to as the “sell-through” revenue recognition method because the vendor does not recognize revenue until the transaction consideration is fixed or determinable, which coincides with the selling of the product through the distribution channel to the end customer. Because the Company does not have reliable information about when its distributors sell the product through to end customers, the Company will use cash collection from distributors as a basis for revenue recognition under the sell-through method. Although in many cases the Company is legally entitled to the accounts receivable at the time of shipment, since the revenue recognition criteria has not been met, the Company has not recognized accounts receivables or any corresponding deferred revenues associated with these transactions.
	As part of the review, the Company also considered the accounting treatment for the related cost of sales when distributor revenue is recognized on a sell-through basis. Previously, cost of sales were recognized upon shipment; however, the Company believes the matching of the recognition of costs of sales with revenue is preferred and therefore considered if such costs should be deferred until revenue is recognized on a sell-through basis. In making this assessment, the Company considered the financial viability of its distributors based on their creditworthiness to determine if collectability of amounts sufficient to realize the costs of the products shipped was reasonably assured at the time of shipment to these distributors. In instances where the distributor was determined to be financially viable, the Company determined that costs of sales should be deferred until the revenue is recognized. For those distributors where the Company has concluded that collectability was not reasonably assured, the Company has expensed the related cost of sales upon shipment.
	Based on the results of the Independent Review, the Company determined that all distributor transactions should be transitioned to the sell-through method of accounting as of the dates described below:
		•		For distributor transactions within the Company’s Orthopedics division, the Company has determined that sell-through accounting should be applied within the Brazil subsidiary for all prior periods given the frequency with which the Company conducted business under extra-contractual and undocumented terms, as well as the Company’s inability to fully access underlying transactional and other information that would be necessary to evaluate transactions under a sell-in basis. For distributor transactions within the division outside the Brazil subsidiary, there were also sales to four distributors that did not meet the fixed or determinable or collectability revenue recognition criteria and therefore, such sales were adjusted to sell-through accounting in the restatement.
		•		For distributor transactions within the Company’s U.S. Spine division, the Company has determined that sell-through accounting should be applied beginning January 1, 2011. Following its consideration of the information provided from the Independent Review, the Company believes that January 1, 2011 is the date extra-contractual terms became pervasive in the Company’s U.S. business, and it is unaware of circumstances existing prior to that date that would require it to broadly apply sell-through accounting to all distributor transactions within the U.S. Spine division. Additionally, there were sales in 2012 and 2011 for which revenue was previously recognized that did not meet the fixed or determinable criteria and the product associated with such sales was subsequently returned in 2013 (i) under the terms of negotiated agreements whereby the Company terminated its relationships with two distributors and (ii) by an additional distributor who returned certain product sold pursuant to a contingent sales arrangement. Such sales represented approximately $3.3 million for the year ended December 31, 2012. Due to the return of the product, no revenue will be recognized for these transactions.
		•		The Company has determined that stimulation products sold to distributors within the Company’s U.S. Spine division during 2012 did not meet the fixed or determinable (and in some cases, collectability) revenue recognition criterion at the time of shipment. Therefore, the Company has determined that sell-through accounting should be applied for these sales. Management also determined that many of these distributors (or affiliates thereof) received commission payments as part of the sales transactions, which the Company previously recorded as sales and marketing expense. The Company has recorded adjustments in the restatement to net these commission expenses against revenue, as they represented product discounts.
		•		The Company has determined that it will prospectively apply sell-through accounting for all remaining distributor arrangements (which entails arrangements within the Company’s Orthopedics division outside the Brazil subsidiary) beginning April 1, 2013, the earliest date for which financial statements have not previously been issued by the Company. Although the Independent Review did not provide information to indicate extra-contractual terms or that historical revenue recognition was inappropriate in these remaining instances, the Company believes the information from the Independent Review indicating that the Company has a history of extra-contractual arrangements for distributor transactions, as described above, provides additional information which should be considered in reassessing the application of sell-through accounting on a prospective basis, particularly given that the Company believes that there is a higher risk associated with distributor arrangements generally.
	The effect of adjustments made to the Company’s previously filed consolidated statements of operations as a result of these matters are shown in the tables below. These adjustments also had the following effects on the Company’s previously filed consolidated balance sheets:
		•		Accounts receivable decreased as of March 31, 2013 and December 31, 2012 by $34.3 million and $41.3 million, respectively, related to the de-recognition of receivables for which revenue has been deferred and will now be recognized on a sell-through basis, based on cash collections.
		•		Inventory increased as of March 31, 2013 and December 31, 2012 by $8.8 million and $11.0 million, respectively, to recognize the costs of inventory shipments to distributors determined to be financially viable as discussed previously.
	Inventory Reserves
	The Company also identified material errors in inventory reserves. One error related to the Company recording an increase of $1.2 million to the Company’s excess and obsolete reserve in the second quarter of 2012 related to a product within the Spine business that was subsequently reversed by the Company in the fourth quarter of 2012. During the Company’s review, it was determined that removing the reserve in the fourth quarter of 2012 was not correct; therefore the reserve has been reinstated.
	The Company has also determined that certain inconsistencies existed with respect to how the Company previously computed and recorded inventory reserves. As a result, the Company has reviewed the methodologies used to compute and record inventory reserves and determined that errors in the application of GAAP existed in prior periods, which required adjustment in these financial statements. Based on this review, the Company has determined that it previously made reductions to previously recorded reserves based on changes in forecasted demand, which it believes was contrary to guidance set forth in ASC Topic 330, Inventory (specifically ASC 330-10-35-14), which states that a write-down of inventory to the lower-of-cost-or-market value at the close of a fiscal year creates a new cost basis that subsequently should not be marked up based on changes in underlying circumstances. The restated consolidated financial statements contain several adjustments to reflect recomputed inventory reserves in each of the relevant periods.
	These adjustments resulted in a decrease to inventory (due to an increase in reserves) as of March 31, 2013 and December 31, 2012 of $14.8 million and $14.8 million, respectively.
	Royalties
	The Company also reviewed the accounting for royalties and determined there were royalties classified as sales and marketing expense; however, such royalties were based on sales of products and were paid to doctors who consulted on development of those products. Given these amounts are attributable to the cost of producing our products, we determined they are correctly classified as cost of goods sold.
	Other Adjustments
	In addition to the adjustments recorded to address the Company’s errors in accounting for distributor revenue recognition, inventory reserves, and royalties, the Company has identified other errors that are generally not material, individually or in the aggregate, but have been recorded in connection with the restatement.
	There were no material impacts to the statements of cash flows for the items above. The results of the adjustments to the Company’s previously filed consolidated statements of operations detailed above are summarized in the tables below. The tax effect of the adjustments is estimated based on the Company’s effective tax rate.
			Three Months Ended March 31, 2013
						Adjustments by Category
			Previously			Distributor			Inventory									Total
	(U.S. Dollars, in thousands)		Reported			Revenue			Reserves			Royalties			Other			Adjustments			Restated
	Net sales		$	100,254		$	2,963		$	—		$	—		$	156		$	3,119		$	103,373
	Cost of sales			22,699			471			86			2,030			331			2,918			25,617
	Gross profit			77,555			2,492			(86	)		(2,030	)		(175	)		201			77,756
	Operating expenses
	Sales and marketing			48,839			(2,073	)		—			(2,030	)		318			(3,785	)		45,054
	General and administrative			18,788			—			—			—			(458	)		(458	)		18,330
	Research and development			5,400			—			—			—			341			341			5,741
	Amortization of intangibles assets			504			—			—			—			40			40			544
	Charges related to U.S. Government resolutions			—			—			—			—			—			—			—
				73,531			(2,073	)		—			(2,030	)		241			(3,862	)		69,669
	Operating income			4,024			4,565			(86	)		—			(416	)		4,063			8,087
	Other income and (expense)			4,204			—			—			—			—			—			4,204
	Income before income taxes			8,228			4,565			(86	)		—			(416	)		4,063			12,291
	Income tax expense			(3,320	)		(1,529	)		29			—			139			(1,361	)		(4,681	)
	Net income from continuing operations, net of tax		$	4,908		$	3,036		$	(57	)	$	—		$	(277	)	$	2,702		$	7,610
			Three Months Ended March 31, 2012
						Adjustments by Category
			Previously			Distributor			Inventory									Total
	(U.S. Dollars, in thousands)		Reported			Revenue			Reserves			Royalties			Other			Adjustments			Restated
	Net sales		$	116,042		$	(7,394	)	$	—		$	—		$	288		$	(7,106	)	$	108,936
	Cost of sales			21,940			(1,471	)		(1,212	)		2,126			(5	)		(562	)		21,378
	Gross profit			94,102			(5,923	)		1,212			(2,126	)		293			(6,544	)		87,558
	Operating expenses
	Sales and marketing			49,521			(417	)		—			(2,126	)		150			(2,393	)		47,128
	General and administrative			14,570			—			—			—			—			—			14,570
	Research and development			7,050			—			—			—			—			—			7,050
	Amortization of intangibles assets			530			—			—			—			50			50			580
	Charges related to U.S. Government resolutions			—			—			—			—			310			310			310
				71,671			(417	)		—			(2,126	)		510			(2,033	)		69,638
	Operating income			22,431			(5,506	)		1,212			—			(217	)		(4,511	)		17,920
	Other income and (expense)			(2,852	)		—			—			—			—			—			(2,852	)
	Income before income taxes			19,579			(5,506	)		1,212			—			(217	)		(4,511	)		15,068
Income tax expense			(7,363	)		1,089			(240	)		—			43			892			(6,471	)
Net income from continuing operations, net of tax		$	12,216		$	(4,417	)	$	972		$	—		$	(174	)	$	(3,619	)	$	8,597
The effects of the restatement on the Company’s condensed consolidated balance sheet as of March 31, 2013 are as follows:
(Unaudited, U.S. Dollars, in thousands, except share data)		As of March 31, 2013
		Previously			Adjustments			Restated
		Reported
Assets
Current assets:
Cash and cash equivalents		$	33,675		$	—		$	33,675
Restricted cash			29,446			—			29,446
Trade accounts receivable, less allowances of $11,731			132,425			(35,919	)		96,506
Inventories			92,133			(7,442	)		84,691
Deferred income taxes			17,363			16,552			33,915
Prepaid expenses and other current assets			32,211			2,179			34,390
Total current assets			337,253			(24,630	)		312,623
Property, plant and equipment, net			52,402			1,717			54,119
Patents and other intangible assets, net			6,765			170			6,935
Goodwill			72,607			—			72,607
Deferred income taxes			20,200			(1,024	)		19,176
Other long-term assets			14,153			(3,855	)		10,298
Total assets		$	503,380		$	(27,622	)	$	475,758
Liabilities and shareholders’ equity
Current liabilities:
Trade accounts payable		$	14,230		$	757		$	14,987
Other current liabilities			51,295			(6,566	)		44,729
Total current liabilities			65,525			(5,809	)		59,716
Long-term debt			20,000			—			20,000
Deferred income taxes			11,460			765			12,225
Other long-term liabilities			4,227			6,198			10,425
Total liabilities			101,212			1,154			102,366
Contingencies (Note 17)
Shareholders’ equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 19,453,294 issued and outstanding			1,945			—			1,945
Additional paid-in capital			250,186			195			250,381
Retained earnings			150,665			(31,318	)		119,347
Accumulated other comprehensive income			(628	)		2,347			1,719
Total shareholders’ equity			402,168			(28,776	)		373,392
Total liabilities and shareholders’ equity		$	503,380		$	(27,622	)	$	475,758
The effects of the restatement on the Company’s condensed consolidated balance sheet as of December 31, 2012 are as follows:
(Unaudited, U.S. Dollars, in thousands, except share data)		As of December 31, 2012
		Previously			Adjustments			Restated
		Reported
Assets
Current assets:
Cash and cash equivalents		$	31,055		$	—		$	31,055
Restricted cash			21,314			—			21,314
Trade accounts receivable, less allowances of $13,543			150,316			(43,004	)		107,312
Inventories			88,744			(5,371	)		83,373
Deferred income taxes			16,959			16,491			33,450
Prepaid expenses and other current assets			32,056			2,023			34,079
Total current assets			340,444			(29,861	)		310,583
Property, plant and equipment, net			51,362			2,473			53,835
Patents and other intangible assets, net			6,880			410			7,290
Goodwill			74,388			—			74,388
Deferred income taxes			19,904			(1,023	)		18,881
Other long-term assets			11,303			(3,383	)		7,920
Total assets		$	504,281		$	(31,384	)	$	472,897
Liabilities and shareholders’ equity
Current liabilities:
Trade accounts payable		$	21,812		$	763		$	22,575
Other current liabilities			46,985			(7,375	)		39,610
Total current liabilities			68,797			(6,612	)		62,185
Long-term debt			20,000			—			20,000
Deferred income taxes			11,456			—			11,456
Other long-term liabilities			4,930			6,494			11,424
Total liabilities			105,183			(118	)		105,065
Contingencies (Note 17)
Shareholders’ equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding			1,934			—			1,934
Additional paid-in capital			246,111			195			246,306
Retained earnings			148,549			(33,702	)		114,847
Accumulated other comprehensive income			2,504			2,241			4,745
Total shareholders’ equity			399,098			(31,266	)		367,832
Total liabilities and shareholders’ equity		$	504,281		$	(31,384	)	$	472,897
The effects of the restatements on the Company’s condensed consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2013 are as follows:
(Unaudited, U.S. Dollars, in thousands, except share and per share data)		Three Months Ended March 31, 2013
		Previously			Adjustments			Restated
		Reported
Product sales		$	88,358		$	2,978		$	91,336
Marketing service fees			11,896			141			12,037
Net sales			100,254			3,119			103,373
Cost of sales			22,699			2,918			25,617
Gross profit			77,555			201			77,756
Operating expenses
Sales and marketing			48,839			(3,785	)		45,054
General and administrative			18,788			(458	)		18,330
Research and development			5,400			341			5,741
Amortization of intangible assets			504			40			544
			73,531			(3,862	)		69,669
Operating income			4,024			4,063			8,087
Other income and expense
Interest expense, net			(560	)		—			(560	)
Other income			4,764			—			4,764
			4,204			—			4,204
Income before income taxes			8,228			4,063			12,291
Income tax expense			(3,320	)		(1,361	)		(4,681	)
Net income from continuing operations, net of tax			4,908			2,702			7,610
Discontinued operations (Note 16)
Loss from discontinued operations			(4,432	)		(2	)		(4,434	)
Income tax benefit			1,640			(316	)		1,324
Net loss from discontinued operations, net of tax			(2,792	)		(318	)		(3,110	)
Net income		$	2,116		$	2,384		$	4,500
Net income (loss) per common share- basic:
Net income from continuing operations, net of tax		$	0.25		$	0.14		$	0.39
Net loss from discontinued operations, net of tax			(0.14	)		(0.02	)		(0.16	)
Net income per common share- basic		$	0.11		$	0.12		$	0.23
Net income (loss) per common share- diluted:
Net income from continuing operations, net of tax		$	0.25		$	0.14		$	0.39
Net loss from discontinued operations, net of tax			(0.14	)		(0.02	)		(0.16	)
Net income per common share- diluted		$	0.11		$	0.12		$	0.23
Weighted average number of common shares:
Basic			19,431,093			—			19,431,093
Diluted			19,691,141			—			19,691,141
Comprehensive (loss) income		$	(1,016	)	$	2,490		$	1,474
The effects of the restatements on the Company’s condensed consolidated statement of operations and comprehensive income for the three months ended March 31, 2012 are as follows:
(Unaudited, U.S. Dollars, in thousands, except share and per share data)		Three Months Ended March 31, 2012
		Previously			Adjustments			Restated
		Reported
Product sales		$	104,820		$	(7,212	)	$	97,608
Marketing service fees			11,222			106			11,328
Net sales			116,042			(7,106	)		108,936
Cost of sales			21,940			(562	)		21,378
Gross profit			94,102			(6,544	)		87,558
Operating expenses
Sales and marketing			49,521			(2,393	)		47,128
General and administrative			14,570			—			14,570
Research and development			7,050			—			7,050
Amortization of intangible assets			530			50			580
Charges related to US Government Resolutions			—			310			310
			71,671			(2,033	)		69,638
Operating income			22,431			(4,511	)		17,920
Other income and expense
Interest expense, net			(2,221	)		—			(2,221	)
Other expense, net			(631	)		—			(631	)
			(2,852	)		—			(2,852	)
Income before income taxes			19,579			(4,511	)		15,068
Income tax expense			(7,363	)		892			(6,471	)
Net income from continuing operations, net of tax			12,216			(3,619	)		8,597
Discontinued operations (Note 16)
(Loss) income from discontinued operations			(506	)		1,033			527
Income tax benefit			306			(23	)		283
Net (loss) income from discontinued operations, net of tax			(200	)		1,010			810
Net income		$	12,016		$	(2,609	)	$	9,407
Net income (loss) per common share- basic:
Net income from continuing operations, net of tax		$	0.65		$	(0.19	)	$	0.46
Net (loss) income from discontinued operations, net of tax			(0.01	)		0.05			0.04
Net income per common share- basic		$	0.64		$	(0.14	)	$	0.5
Net income (loss) per common share- diluted:
Net income from continuing operations, net of tax		$	0.64		$	(0.19	)	$	0.45
Net (loss) income from discontinued operations, net of tax			(0.01	)		0.05			0.04
Net income per common share- diluted		$	0.63		$	(0.14	)	$	0.49
Weighted average number of common shares:
Basic			18,675,694			—			18,675,694
Diluted			19,116,195			—			19,116,195
Comprehensive income		$	14,726		$	(2,918	)	$	11,808

Inventories

Inventories	3 Months Ended
	Mar. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	3. Inventories
	Inventories are valued at the lower of cost or estimated net realizable value, after provision for excess, obsolete or impaired items which is reviewed and updated on a periodic basis by management. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Italy, cost is determined on a weighted-average basis, which approximates the first in, first out (“FIFO”) method due to the high turn-over rate of inventory at this location. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Texas, standard costs, which approximates actual cost on a FIFO basis, is used to value inventory. Standard costs are reviewed annually by management, or more often in the event circumstances indicate a change in cost has occurred. The valuation of work-in-process, finished products, field inventory and consignment inventory includes the cost of materials, labor and production costs. Field inventory represents immediately saleable finished products inventory that is in the possession of the Company’s direct sales representatives. Consignment inventory represents immediately saleable finished products located at third party customers, such as distributors and hospitals. Deferred cost of sales result from transactions where the Company has shipped product or performed services for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the deferred revenues and associated cost of sales are recognized.
	(US$ in thousands)	March 31,		December 31,
		2013		2012
		(Restated)		(Restated)
	Raw materials	$	5,847	$	7,623
	Work-in-process		7,401		7,886
	Finished products		33,234		28,308
	Field inventory		22,963		22,629
	Consignment inventory		5,765		6,155
	Deferred cost of sales		9,481		10,772
	Total Inventory	$	84,691	$	83,373

Patents_and_other_intangible_a

Patents and other intangible assets	3 Months Ended
	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Patents and other intangible assets	'
	4. Patents and other intangible assets
	(US$ in thousands)	March 31,			December 31,
		2013			2012
		(Restated)			(Restated)
	Cost
	Patents	$	39,000		$	38,905
	Trademarks — definite lived		679			657
			39,679			39,562
	Accumulated amortization
	Patents		(32,292	)		(31,845	)
	Trademarks — definite lived		(452	)		(427	)
			(32,744	)		(32,272	)
	Patents and other intangible assets, net	$	6,935		$	7,290

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	5. Goodwill
	The following table presents the changes in the net carrying value of goodwill:
	(US$ in thousands)	Total
	At December 31, 2012	$	74,388
	Foreign currency		(1,781	)
	At March 31, 2013	$	72,607

Bank_borrowings

Bank borrowings	3 Months Ended
	Mar. 31, 2013
Debt Disclosure [Abstract]	'
Bank borrowings	'
	6. Bank borrowings
	Borrowings under lines of credit consist of borrowings in Euros used to fund international operations. There were no borrowings under such facilities at March 31, 2013 and $0.1 million at December 31, 2012. The weighted average interest rates on borrowings under the line of credit at December 31, 2012 was 3.70%.
	The Company had an unused available line of credit of €5.8 million ($7.4 million) and €5.8 million ($7.6 million) at March 31, 2013 and December 31, 2012, respectively, in its Italian line of credit. This line of credit provides the Company the option to borrow amounts in Italy at rates which are determined at the time of borrowing. This line of credit is unsecured.

Longterm_debt

Long-term debt	3 Months Ended
	Mar. 31, 2013
Debt Disclosure [Abstract]	'
Long-term debt	'
	7. Long-term debt
	On August 30, 2010, the Company’s wholly-owned U.S. holding company, Orthofix Holdings, Inc. (“Orthofix Holdings”) entered into a Credit Agreement (the “Credit Agreement”) with certain domestic direct and indirect subsidiaries of the Company (the “Guarantors”), JPMorgan Chase Bank, N.A., as Administrative Agent, RBS Citizens, N.A., as Syndication Agent, and certain lender parties thereto.
	The Credit Agreement provides for a five year, $200 million secured revolving credit facility (the “Revolving Credit Facility”), and a five year, $100 million secured term loan facility (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”). Orthofix Holdings has the ability to increase the amount of the Credit Facilities by an aggregate amount of up to $50 million upon satisfaction of certain conditions.
	In May 2012, the Company used a portion of the proceeds from the sale of Breg, Inc. (“Breg”) (see Note 16) to repay in full the remaining $87.5 million balance on the Term Loan Facility and pay down $57.5 million of amounts outstanding under the Revolving Credit Facility. This use of proceeds was required by the lenders’ consent dated April 23, 2012 to the Credit Agreement. As a result of the sale of Breg, Breg ceased to be a subsidiary of the Company and, therefore, Breg was released as a credit party under the Credit Agreement. Additionally, the Company paid $20 million in June 2012 and $20 million in September 2012 to reduce amounts outstanding under the Revolving Credit Facility. As a result, at December 31, 2012, the Term Loan Facility had been repaid in full and there was $20 million outstanding under the Revolving Credit Facility as of March 31, 2013 and December 31, 2012. Borrowings under the Credit Facilities bear interest at a floating rate, which is, at Orthofix Holdings’ option, either the London Inter-Bank Offered Rate (“LIBOR”) plus an applicable margin or a base rate (as defined in the Credit Agreement) plus an applicable margin (in each case subject to adjustment based on financial ratios). Such applicable margin will be up to 3.25% for LIBOR borrowings and up to 2.25% for base rate borrowings depending upon a measurement of the consolidated leverage ratio with respect to the immediately preceding four fiscal quarters. As of March 31, 2013 and December 31, 2012, the entire Revolving Credit Facility was at the LIBOR rate plus a margin of 2.50%. The effective interest rate on the Credit Facilities as of March 31, 2013 and December 31, 2012 was 2.7%.
	Outstanding balances on the Revolving Credit Facility are due on August 30, 2015.
	Borrowings under the Revolving Credit Facility, which may be made in the future, will be used for working capital, capital expenditures and other general corporate purposes of Orthofix Holdings and its subsidiaries. The Guarantors have guaranteed repayment of Orthofix Holdings’ obligations under the Credit Agreement. The obligations of Orthofix Holdings and each of the Guarantors with respect to the Credit Facilities are secured by a pledge of substantially all of the assets of Orthofix Holdings and each of the Guarantors.
	The Credit Agreement, as amended, requires Orthofix Holdings and the Company to comply with coverage ratios on a consolidated basis and contains affirmative and negative covenants, including limitations on additional debt, liens, investments and acquisitions. The Credit Agreement, as amended, also includes events of default customary for facilities of this type. Upon the occurrence of an event of default, all outstanding loans may be accelerated and/or the lenders’ commitments terminated. The Company was in compliance with the affirmative and negative covenants at March 31, 2013 and there were no events of default.
	Certain subsidiaries of the Company have restrictions on their ability to pay dividends or make intercompany loan advances pursuant to the Company’s Credit Facilities. The net assets of Orthofix Holdings and its subsidiaries are restricted for distributions to the parent company. Domestic subsidiaries of the Company, as parties to the credit agreement, have access to these net assets for operational purposes.
	The amount of restricted net assets of Orthofix Holdings and its subsidiaries as of March 31, 2013 and December 31, 2012 is $225.2 million and $213.4 million, respectively. In addition, the Credit Agreement restricts the Company and subsidiaries that are not parties to the Credit Facilities from access to cash held by Orthofix Holdings, Inc. and its subsidiaries. All of the Company’s subsidiaries that are parties to the Credit Agreement have access to this cash for operational and debt repayment purposes. The amount of restricted cash of the Company as of March 31, 2013 and December 31, 2012 was $29.4 million and $21.3 million, respectively.
	In conjunction with obtaining the Credit Facilities and the Credit Agreement, as amended, the Company incurred debt issuance costs of $5 million. These costs are being amortized using the effective interest method over the life of the Credit Facilities. In conjunction with the Term Loan Facility repayment in May 2012, the Company wrote off $0.8 million of related debt issuance costs. As of March 31, 2013 and December 31, 2012, debt issuance costs, net of accumulated amortization, related to the Credit Agreement were $1.6 million and $1.8 million, respectively.

Derivative_instruments

Derivative instruments	3 Months Ended
	Mar. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative instruments	'
	8. Derivative instruments
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) or net income (loss).
	(US$ in thousands)	Fair value: favorable			Balance sheet location
	As of March 31, 2013	(unfavorable)
	Cross-currency swap	$	1,598		Other long-term assets
	As of December 31, 2012
	Cross-currency swap	$	305		Other long-term assets
		Three Months Ended
		March 31,
	(US$ in thousands)	2013			2012
	Cross-currency swap unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	$	(318	)	$	509
	Cross-currency swap
	On September 30, 2010, the Company entered into a cross-currency swap agreement (the “replacement swap agreement”) with JPMorgan Chase Bank and Royal Bank of Scotland PLC (the “counterparties”) to manage its cash flows related to foreign currency exposure for a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro.
	Under the terms of the swap agreement, the Company pays Euros based on a €28.7 million notional value and a fixed rate of 5.00% and receives U.S. dollars based on a notional value of $39 million and a fixed rate of 4.635%. The expiration date is December 30, 2016, the date upon which the underlying intercompany debt, to which the swap agreement applies, matures. The swap agreement is designated as a cash flow hedge and therefore the Company recognized an unrealized gain (loss) on the change in fair value, net of tax, within other comprehensive income (loss).

Fair_value_measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value measurements	'
	9. Fair value measurements
	Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Non-financial assets and liabilities of the Company measured at fair value include any long-lived assets or equity method investments that are impaired in a currently reported period. The authoritative guidance also describes three levels of inputs that may be used to measure fair value:
		Level 1 —		quoted prices in active markets for identical assets and liabilities
		Level 2 —		observable inputs other than quoted prices in active markets for identical assets and liabilities
		Level 3 —		unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	As of March 31, 2013, the Company’s financial instruments included cash equivalents, restricted cash, accounts receivable, short-term bank borrowings, accounts payable, long-term secured debt, and a cross currency derivative contract. Cash equivalents consist of short-term, highly liquid, income-producing investments, all of which have original maturities of 90 days or less, including money market funds. The carrying value of restricted cash, accounts receivable, short-term bank borrowings and accounts payable approximate fair value due to the short-term maturities of these instruments. The Company’s credit facilities carry a floating rate of interest, and therefore, the carrying value is considered to approximate the fair value.
	The Company’s cross-currency derivative instrument is the only financial instrument recorded at fair value on a recurring basis. This instrument consists of an over-the-counter contract, which is not traded on a public exchange. The fair value of the swap contract is determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets. Therefore, the Company has categorized the swap contract as a Level 2 derivative financial instrument. The Company also considers counterparty credit risk and its own credit risk in its determination of all estimated fair values. The Company has consistently applied these valuation techniques in all periods presented.
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(US$ in thousands)	Balance			Level 1		Level 2		Level 3
		March 31,
		2013
	Derivative financial instruments
	Cash flow hedges
	Cross-currency swap	$	1,598		$	—	$	1,598	$	—
	(US$ in thousands)	Balance			Level 1		Level 2		Level 3
		December 31,
		2012
	Derivative financial instruments
	Cash flow hedges
	Cross currency swap	$	305		$	—	$	305	$	—

Comprehensive_income_loss

Comprehensive income (loss)	3 Months Ended
	Mar. 31, 2013
Equity [Abstract]	'
Comprehensive income (loss)	'
	10. Comprehensive income (loss)
	Accumulated other comprehensive income is comprised of foreign currency translation adjustments and the effective portion of the gain (loss) on the Company’s cross-currency swap, which is designated and accounted for as a cash flow hedge. The components of and changes in accumulated other comprehensive income were as follows:
	(US$ in thousands)		Foreign			Fair Value of			Accumulated
			Currency			Cross-			Other
			Translation			Currency			Comprehensive
			Adjustments			Swap			Income
	Balance at December 31, 2012		$	4,614		$	131		$	4,745
	Unrealized gain on cross-currency swap, net of tax of $187			—			(318	)		(318	)
	Foreign currency translation adjustment (1)			(2,708	)		—			(2,708	)
	Balance at March 31, 2013		$	1,906		$	(187	)	$	1,719
	-1	As the cash generally remains permanently invested in the non-U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share

Earnings per share	3 Months Ended
	Mar. 31, 2013
Earnings Per Share [Abstract]	'
Earnings per share	'
	11. Earnings per share
	For the three months ended March 31, 2013 and 2012, there were no adjustments to net income for purposes of calculating basic and diluted net income available to common shareholders. The following is a reconciliation of the weighted average shares used in the basic and diluted net income per common share computations.
		Three Months Ended
		March 31,
		2013		2012
	Weighted average common shares-basic		19,431,093		18,675,694
	Effect of dilutive securities:
	Unexercised stock options net of treasury share repurchase		260,048		440,501
	Weighted average common shares-diluted		19,691,141		19,116,195
	Options to purchase shares of common stock with exercise prices in excess of the average market price of common shares are not included in the computation of diluted earnings per share. There were 973,037 and 714,686 outstanding options not included in the diluted earnings per share computation for the three months ended March 31, 2013 and 2012, respectively, because the inclusion of these options was anti-dilutive.

Sharebased_compensation

Share-based compensation	3 Months Ended
	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-based compensation	'
	12. Share-based compensation
	All share-based compensation costs are measured at the grant date, based on the estimated fair value of the award, and are recognized as expense in the condensed consolidated statements of operations over the requisite service period.
	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended
		March 31,
	(US$ in thousands)	2013		2012
	Cost of sales	$	287	$	176
	Sales and marketing		436		445
	General and administrative		1,175		770
	Research and development		45		42
	Total	$	1,943	$	1,433
	For the three months ended March 31, 2013 and 2012, there were no performance requirements for share-based compensation awarded to employees. In March 2013, the Company granted options to its newly-appointed Chief Executive Officer, which vesting is based on achieving certain market prices for the Company’s common stock.
	During the three months ended March 31, 2013 and 2012, there were 113,965 and 262,713 shares, respectively, of common stock issued related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards.

Other_income_expense

Other income (expense)	3 Months Ended
	Mar. 31, 2013
Other Income And Expenses [Abstract]	'
Other income (expense)	'
	13. Other income (expense)
	The following table shows the detail of other income (expense):
			Three Months Ended
			March 31,
	(US$ in thousands)		2013			2012
			(Restated)			(Restated)
	Gain related to demutualization of a mutual insurance company (1)		$	4,406		$	—
	Transactional foreign currency exchange gains (losses)			623			(470	)
	Other			(265	)		(161	)
	Total		$	4,764		$	(631	)
	-1	In the first quarter of 2013, the Company received $4.4 million of cash related to the demutualization of a mutual insurance company, in which the company was an eligible member to share in such proceeds.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'
Income taxes	'
	14. Income taxes
	The Company recognized a $4.7 million and $6.5 million provision for income tax which reflects an effective tax rate of 38.1% and 42.9% on pre-tax income for the three months ended March 31, 2013 and 2012, respectively. Excluding the impact of various discrete charges, the effective tax rate on continuing operations was 38.1% and 39.5% for the first three months of 2013 and 2012, respectively. The principal factors affecting the Company’s effective tax rate was the Company’s mix of earnings among various tax jurisdictions, state taxes and current period losses in certain jurisdictions for which the Company does not currently provide a tax benefit.
	On January 2, 2013, the American Taxpayer Relief Act of 2012 (“Act”) was enacted. The Act provides tax relief for businesses by reinstating certain tax benefits and credits retroactively to January 1, 2012. There are several provisions of the Act that impact the Company, most notably the extension of the Research and Development credit. Income tax accounting rules require tax law changes to be recognized in the period of enactment; as such, the associated tax benefits of the Act were recognized in the Company’s provision for income taxes in the first quarter of 2013.
	As of March 31, 2013 and December 31, 2012, the Company’s unrecognized tax benefit was $0.8 million and $1.2 million, respectively. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits in income tax expense. In March 2013 the Company settled a $0.9 million liability that had been previously accrued as of December 31, 2012. The entire amount of unrecognized tax benefits, including interest, would favorably impact the Company’s effective tax rate if recognized. As of March 31, 2013, the Company does not expect the amount of unrecognized tax benefits to change significantly over the next twelve months.
	Unremitted foreign earnings increased from $285.3 million at December 31, 2011 to $292 million at December 31, 2012. The $292 million includes $293.8 million in U.S subsidiaries. The Company does not anticipate any impact on income tax liabilities since earnings are permanently reinvested for both U.S and non-U.S. subsidiaries.

Business_segment_information

Business segment information	3 Months Ended
	Mar. 31, 2013
Segment Reporting [Abstract]	'
Business segment information	'
	15. Business segment information
	The Company’s segment information (as provided below) has been prepared based on the Company’s two global business units (“GBU”) reporting segments, Spine and Orthopedics. The accounting policies of the segments are the same as those described in the business segment information found in Note 13 to the Consolidated Financial Statements included in the 2012 Form 10-K/A.
	The table below presents external net sales by GBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of sales of Trinity Evolution ® in spine and orthopedic applications.
			External Net Sales by GBU
			Three Months Ended March 31,
	(US$ in thousands)		2013			2012			Reported			Constant
									Decline			Currency
												Decline
			(Restated)			(Restated)			(Restated)			(Restated)
	Spine
	Spine Repair Implants and Regenerative Biologics		$	36,280		$	34,393			5	%		0	%
	Spine Regenerative Stimulation			33,744			38,790			(13	)%		(17	)%
	Total Spine			70,024			73,183			(4	)%		(9	)%
	Orthopedics			33,349			35,753			(7	)%		(3	)%
	Total Net Sales		$	103,373		$	108,936			(5	)%		(7	)%
	The table below presents operating income (loss) by GBU reporting segment:
	Operating Income (Loss) by GBU		Three Months Ended
			March 31,
	(US$ in thousands)		2013			2012
			(Restated)			(Restated)
	Spine		$	14,680		$	22,019
	Orthopedics			2,041			71
	Corporate (1)			(8,634	)		(4,170	)
	Total		$	8,087		$	17,920
	-1	For the three months ended March 31, 2013, the operating loss for Corporate included $3.6 million of management succession charges.

Sale_of_Breg_and_Disposition_o

Sale of Breg and Disposition of Sports Medicine GBU	3 Months Ended
	Mar. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Sale of Breg and Disposition of Sports Medicine GBU	'
	16. Sale of Breg and Disposition of Sports Medicine GBU
	On April 23, 2012, the Company’s subsidiary Orthofix Holdings and Breg entered into a stock purchase agreement (the “SPA”) with Breg Acquisition Corp. (“Buyer”), a newly formed affiliate of Water Street Healthcare Partners II, L.P., pursuant to which Buyer agreed to acquire from Orthofix Holdings all the outstanding shares of Breg, subject to the terms and conditions contained therein (the “Transaction”). Under the terms of the SPA, upon closing of the sale, Orthofix Holdings and the Company agreed to indemnify Buyer with respect to certain specified matters, including the government investigation and product liability matters regarding a previously owned infusion pump product line, pre-closing sales of cold therapy units and certain post-closing sales of cold therapy units. (See “Matters Related to the Company’s Former Breg Subsidiary and Possible Indemnification Obligations” under Note 17 to the Consolidated Financial Statements included in the 2012 Form 10-K/A.) On May 24, 2012 (the “Closing Date”), Orthofix Holdings completed the sale of all of the outstanding shares of Breg for $157.5 million in cash. After adjustments for working capital and indebtedness in accordance with the terms of the SPA, Orthofix Holdings used $145 million of the net proceeds to prepay outstanding Company indebtedness, as required by a lender consent received in connection with the Company’s existing Credit Agreement. As a result of the closing of this Transaction, Breg ceased to be a subsidiary of the Company and, therefore, Breg was released as a credit party under the Credit Agreement. The Company also agreed to enter into certain transition arrangements at the closing, including a transition services agreement pursuant to which the Company agreed to continue to provide administrative operational support for a period of up to twelve months. As a result of the sale of Breg, the Company completed its exit from the Sports Medicine GBU, of which Breg was a significant component.
	The portion of indemnification related to post closing claims related to post-closing sales of cold therapy has created a guarantee under Accounting Standards Codification ASC 460 — Guarantees, and the fair value of the liability has been recorded under the initial recognition criteria in the amount of $2 million at the Closing Date. The Company will amortize the fair value of the noncontingent liability ratably over the period of indemnification, which is three years. The Company’s obligations under this guarantee were approximately $1.4 million and $1.6 million as of March 31, 2013 and December 31, 2012, respectively.
	Gain on Sale of Discontinued Operations
	The following table presents the value of the asset disposition, proceeds received, net of various working capital adjustments and indebtedness and net gain on sale of Breg as shown in the condensed consolidated statement of operations for the year ended December 31, 2012.
	(US$ in thousands)	Total
	Cash proceeds	$	157,500
	Less:
	Working Capital		(7,093	)
	Transaction related expenses		(4,276	)
	Fair Value of Indemnification		(2,000	)
	Tangible assets		(8,309	)
	Intangible assets		(28,164	)
	Goodwill		(106,200	)
	Gain on sale of Breg, before income taxes		1,458
	Income tax expense		(113	)
	Gain on sale of Breg, net of taxes	$	1,345
	Included in discontinued operations for the three months ended March 31, 2013 is $4 million of expense related to the Company’s indemnification of certain specified matters described above.
	The Company’s consolidated financial statements and related footnote disclosures reflect the Sports Medicine GBU as discontinued operations. Income (loss) associated with the Sports Medicine GBU, net of applicable income taxes is shown as income (loss) from discontinued operations for all periods presented in accordance with ASC 205-20 Discontinued Operations.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	17. Contingencies
	The Company is a party to certain outstanding legal proceedings, investigations and claims. These matters (including certain matters occurring in 2013) are described in the 2012 Form 10-K/A. There have been no material developments in these matters since the filing of the 2012 Form 10-K/A.

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Event	'
	18. Subsequent Events
	In August 2013, as a result of the delay in filing our second quarter report on Form 10-Q and delay in filing our third quarter report on Form 10-Q, we sought and obtained a Limited Waiver which waived requirements under the Credit Agreement to deliver quarterly financial statements for the fiscal quarters ending on June 30, 2013 and September 30, 2013, and related financial covenant certificates, until the earlier of (i) March 31, 2014 or (ii) the date that is one day after such financial statements are publicly filed or released.
	On May 8, 2013, the Company announced that its Board of Directors has authorized a share repurchase program in an amount up to $50 million. Repurchases began on May 10, 2013 consisting primarily of open market transactions at prevailing market prices in accordance with the guidelines specified under Rule 10b-18 of the Securities Exchange Act of 1934, as amended. Repurchases were being made from cash on hand, cash generated from operations and additional borrowings. The timing of the transactions and the aggregate number of shares of common stock that will be ultimately repurchased under the repurchase program will depend on a variety of factors, including market conditions and the prices at which the securities are repurchased. The Company may discontinue repurchases without prior notice at any time if it determines additional repurchases are not warranted. As of the date of this Form 10-Q/A, the Company has made total repurchases in an amount equal to approximately $39.5 million, all of which repurchases to date were made during the fiscal quarters ended June 30, 2013 and September 30, 2013.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	(a) Basis of presentation
	The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S., have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto of the Company’s 2012 Form 10-K/A. The notes to the unaudited condensed consolidated financial statements are presented on a continuing operations basis unless otherwise noted.
Reclassifications	'
	(b) Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net income or shareholders’ equity.
Use of estimates	'
	(c) Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to the resolution of U.S. government matters, contractual allowances, doubtful accounts, inventories, taxes, shared-based compensation, and potential goodwill and intangible asset impairment. Actual results could differ from these estimates.
Foreign Currency Translation	'
	(d) Foreign Currency Translation
	The financial statements for operations outside the United States are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at year end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity.

Restatement_of_the_Condensed_C1

Restatement of the Condensed Consolidated Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2013
Text Block [Abstract]	'
Adjustments to Previously Filed Consolidated Income Statements	'
	The results of the adjustments to the Company’s previously filed consolidated statements of operations detailed above are summarized in the tables below. The tax effect of the adjustments is estimated based on the Company’s effective tax rate.
		Three Months Ended March 31, 2013
					Adjustments by Category
		Previously			Distributor			Inventory									Total
	(U.S. Dollars, in thousands)	Reported			Revenue			Reserves			Royalties			Other			Adjustments			Restated
	Net sales	$	100,254		$	2,963		$	—		$	—		$	156		$	3,119		$	103,373
	Cost of sales		22,699			471			86			2,030			331			2,918			25,617
	Gross profit		77,555			2,492			(86	)		(2,030	)		(175	)		201			77,756
	Operating expenses
	Sales and marketing		48,839			(2,073	)		—			(2,030	)		318			(3,785	)		45,054
	General and administrative		18,788			—			—			—			(458	)		(458	)		18,330
	Research and development		5,400			—			—			—			341			341			5,741
	Amortization of intangibles assets		504			—			—			—			40			40			544
	Charges related to U.S. Government resolutions		—			—			—			—			—			—			—
			73,531			(2,073	)		—			(2,030	)		241			(3,862	)		69,669
	Operating income		4,024			4,565			(86	)		—			(416	)		4,063			8,087
	Other income and (expense)		4,204			—			—			—			—			—			4,204
	Income before income taxes		8,228			4,565			(86	)		—			(416	)		4,063			12,291
	Income tax expense		(3,320	)		(1,529	)		29			—			139			(1,361	)		(4,681	)
	Net income from continuing operations, net of tax	$	4,908		$	3,036		$	(57	)	$	—		$	(277	)	$	2,702		$	7,610
		Three Months Ended March 31, 2012
					Adjustments by Category
		Previously			Distributor			Inventory									Total
	(U.S. Dollars, in thousands)	Reported			Revenue			Reserves			Royalties			Other			Adjustments			Restated
	Net sales	$	116,042		$	(7,394	)	$	—		$	—		$	288		$	(7,106	)	$	108,936
	Cost of sales		21,940			(1,471	)		(1,212	)		2,126			(5	)		(562	)		21,378
	Gross profit		94,102			(5,923	)		1,212			(2,126	)		293			(6,544	)		87,558
	Operating expenses
	Sales and marketing		49,521			(417	)		—			(2,126	)		150			(2,393	)		47,128
	General and administrative		14,570			—			—			—			—			—			14,570
	Research and development		7,050			—			—			—			—			—			7,050
	Amortization of intangibles assets		530			—			—			—			50			50			580
	Charges related to U.S. Government resolutions		—			—			—			—			310			310			310
			71,671			(417	)		—			(2,126	)		510			(2,033	)		69,638
	Operating income		22,431			(5,506	)		1,212			—			(217	)		(4,511	)		17,920
	Other income and (expense)		(2,852	)		—			—			—			—			—			(2,852	)
	Income before income taxes		19,579			(5,506	)		1,212			—			(217	)		(4,511	)		15,068
	Income tax expense		(7,363	)		1,089			(240	)		—			43			892			(6,471	)
	Net income from continuing operations, net of tax	$	12,216		$	(4,417	)	$	972		$	—		$	(174	)	$	(3,619	)	$	8,597
Effects of Restatement on Condensed Consolidated Balance Sheet	'
	The effects of the restatement on the Company’s condensed consolidated balance sheet as of March 31, 2013 are as follows:
	(Unaudited, U.S. Dollars, in thousands, except share data)	As of March 31, 2013
		Previously			Adjustments			Restated
		Reported
	Assets
	Current assets:
	Cash and cash equivalents	$	33,675		$	—		$	33,675
	Restricted cash		29,446			—			29,446
	Trade accounts receivable, less allowances of $11,731		132,425			(35,919	)		96,506
	Inventories		92,133			(7,442	)		84,691
	Deferred income taxes		17,363			16,552			33,915
	Prepaid expenses and other current assets		32,211			2,179			34,390
	Total current assets		337,253			(24,630	)		312,623
	Property, plant and equipment, net		52,402			1,717			54,119
	Patents and other intangible assets, net		6,765			170			6,935
	Goodwill		72,607			—			72,607
	Deferred income taxes		20,200			(1,024	)		19,176
	Other long-term assets		14,153			(3,855	)		10,298
	Total assets	$	503,380		$	(27,622	)	$	475,758
	Liabilities and shareholders’ equity
	Current liabilities:
	Trade accounts payable	$	14,230		$	757		$	14,987
	Other current liabilities		51,295			(6,566	)		44,729
	Total current liabilities		65,525			(5,809	)		59,716
	Long-term debt		20,000			—			20,000
	Deferred income taxes		11,460			765			12,225
	Other long-term liabilities		4,227			6,198			10,425
	Total liabilities		101,212			1,154			102,366
	Contingencies (Note 17)
	Shareholders’ equity:
	Common shares $0.10 par value; 50,000,000 shares authorized; 19,453,294 issued and outstanding		1,945			—			1,945
	Additional paid-in capital		250,186			195			250,381
	Retained earnings		150,665			(31,318	)		119,347
	Accumulated other comprehensive income		(628	)		2,347			1,719
	Total shareholders’ equity		402,168			(28,776	)		373,392
	Total liabilities and shareholders’ equity	$	503,380		$	(27,622	)	$	475,758
	The effects of the restatement on the Company’s condensed consolidated balance sheet as of December 31, 2012 are as follows:
	(Unaudited, U.S. Dollars, in thousands, except share data)	As of December 31, 2012
		Previously			Adjustments			Restated
		Reported
	Assets
	Current assets:
	Cash and cash equivalents	$	31,055		$	—		$	31,055
	Restricted cash		21,314			—			21,314
	Trade accounts receivable, less allowances of $13,543		150,316			(43,004	)		107,312
	Inventories		88,744			(5,371	)		83,373
	Deferred income taxes		16,959			16,491			33,450
	Prepaid expenses and other current assets		32,056			2,023			34,079
	Total current assets		340,444			(29,861	)		310,583
	Property, plant and equipment, net		51,362			2,473			53,835
	Patents and other intangible assets, net		6,880			410			7,290
	Goodwill		74,388			—			74,388
	Deferred income taxes		19,904			(1,023	)		18,881
	Other long-term assets		11,303			(3,383	)		7,920
	Total assets	$	504,281		$	(31,384	)	$	472,897
	Liabilities and shareholders’ equity
	Current liabilities:
	Trade accounts payable	$	21,812		$	763		$	22,575
	Other current liabilities		46,985			(7,375	)		39,610
	Total current liabilities		68,797			(6,612	)		62,185
	Long-term debt		20,000			—			20,000
	Deferred income taxes		11,456			—			11,456
	Other long-term liabilities		4,930			6,494			11,424
Total liabilities		105,183			(118	)		105,065
Contingencies (Note 17)
Shareholders’ equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding		1,934			—			1,934
Additional paid-in capital		246,111			195			246,306
Retained earnings		148,549			(33,702	)		114,847
Accumulated other comprehensive income		2,504			2,241			4,745
Total shareholders’ equity		399,098			(31,266	)		367,832
Total liabilities and shareholders’ equity	$	504,281		$	(31,384	)	$	472,897
Effects of Restatement on Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)	'
	The effects of the restatements on the Company’s condensed consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2013 are as follows:
	(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Three Months Ended March 31, 2013
		Previously			Adjustments			Restated
		Reported
	Product sales	$	88,358		$	2,978		$	91,336
	Marketing service fees		11,896			141			12,037
	Net sales		100,254			3,119			103,373
	Cost of sales		22,699			2,918			25,617
	Gross profit		77,555			201			77,756
	Operating expenses
	Sales and marketing		48,839			(3,785	)		45,054
	General and administrative		18,788			(458	)		18,330
	Research and development		5,400			341			5,741
	Amortization of intangible assets		504			40			544
			73,531			(3,862	)		69,669
	Operating income		4,024			4,063			8,087
	Other income and expense
	Interest expense, net		(560	)		—			(560	)
	Other income		4,764			—			4,764
			4,204			—			4,204
	Income before income taxes		8,228			4,063			12,291
	Income tax expense		(3,320	)		(1,361	)		(4,681	)
	Net income from continuing operations, net of tax		4,908			2,702			7,610
	Discontinued operations (Note 16)
	Loss from discontinued operations		(4,432	)		(2	)		(4,434	)
	Income tax benefit		1,640			(316	)		1,324
	Net loss from discontinued operations, net of tax		(2,792	)		(318	)		(3,110	)
	Net income	$	2,116		$	2,384		$	4,500
	Net income (loss) per common share- basic:
	Net income from continuing operations, net of tax	$	0.25		$	0.14		$	0.39
	Net loss from discontinued operations, net of tax		(0.14	)		(0.02	)		(0.16	)
	Net income per common share- basic	$	0.11		$	0.12		$	0.23
	Net income (loss) per common share- diluted:
	Net income from continuing operations, net of tax	$	0.25		$	0.14		$	0.39
	Net loss from discontinued operations, net of tax		(0.14	)		(0.02	)		(0.16	)
	Net income per common share- diluted	$	0.11		$	0.12		$	0.23
	Weighted average number of common shares:
	Basic		19,431,093			—			19,431,093
	Diluted		19,691,141			—			19,691,141
	Comprehensive (loss) income	$	(1,016	)	$	2,490		$	1,474
	The effects of the restatements on the Company’s condensed consolidated statement of operations and comprehensive income for the three months ended March 31, 2012 are as follows:
	(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Three Months Ended March 31, 2012
		Previously			Adjustments			Restated
		Reported
	Product sales	$	104,820		$	(7,212	)	$	97,608
	Marketing service fees		11,222			106			11,328
	Net sales		116,042			(7,106	)		108,936
	Cost of sales		21,940			(562	)		21,378
	Gross profit		94,102			(6,544	)		87,558
	Operating expenses
	Sales and marketing		49,521			(2,393	)		47,128
	General and administrative		14,570			—			14,570
	Research and development		7,050			—			7,050
	Amortization of intangible assets		530			50			580
	Charges related to US Government Resolutions		—			310			310
			71,671			(2,033	)		69,638
	Operating income		22,431			(4,511	)		17,920
	Other income and expense
	Interest expense, net		(2,221	)		—			(2,221	)
	Other expense, net		(631	)		—			(631	)
			(2,852	)		—			(2,852	)
	Income before income taxes		19,579			(4,511	)		15,068
	Income tax expense		(7,363	)		892			(6,471	)
Net income from continuing operations, net of tax		12,216			(3,619	)		8,597
Discontinued operations (Note 16)
(Loss) income from discontinued operations		(506	)		1,033			527
Income tax benefit		306			(23	)		283
Net (loss) income from discontinued operations, net of tax		(200	)		1,010			810
Net income	$	12,016		$	(2,609	)	$	9,407
Net income (loss) per common share- basic:
Net income from continuing operations, net of tax	$	0.65		$	(0.19	)	$	0.46
Net (loss) income from discontinued operations, net of tax		(0.01	)		0.05			0.04
Net income per common share- basic	$	0.64		$	(0.14	)	$	0.5
Net income (loss) per common share- diluted:
Net income from continuing operations, net of tax	$	0.64		$	(0.19	)	$	0.45
Net (loss) income from discontinued operations, net of tax		(0.01	)		0.05			0.04
Net income per common share- diluted	$	0.63		$	(0.14	)	$	0.49
Weighted average number of common shares:
Basic		18,675,694			—			18,675,694
Diluted		19,116,195			—			19,116,195
Comprehensive income	$	14,726		$	(2,918	)	$	11,808

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	US$ in thousands)	March 31,		December 31,
		2013		2012
		(Restated)		(Restated)
	Raw materials	$	5,847	$	7,623
	Work-in-process		7,401		7,886
	Finished products		33,234		28,308
	Field inventory		22,963		22,629
	Consignment inventory		5,765		6,155
	Deferred cost of sales		9,481		10,772
	Total Inventory	$	84,691	$	83,373

Patents_and_other_intangible_a1

Patents and other intangible assets (Tables)	3 Months Ended
	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Patents and Other Intangible Assets	'
	(US$ in thousands)	March 31,			December 31,
		2013			2012
		(Restated)			(Restated)
	Cost
	Patents	$	39,000		$	38,905
	Trademarks — definite lived		679			657
			39,679			39,562
	Accumulated amortization
	Patents		(32,292	)		(31,845	)
	Trademarks — definite lived		(452	)		(427	)
			(32,744	)		(32,272	)
	Patents and other intangible assets, net	$	6,935		$	7,290

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Changes in Net Carrying Amount of Goodwill	'
	The following table presents the changes in the net carrying value of goodwill:
	(US$ in thousands)	Total
	At December 31, 2012	$	74,388
	Foreign currency		(1,781	)
	At March 31, 2013	$	72,607

Derivative_instruments_Tables

Derivative instruments (Tables)	3 Months Ended
	Mar. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Schedule of Fair Values of Derivative Instruments	'
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) or net income (loss).
	(US$ in thousands)	Fair value: favorable			Balance sheet location
	As of March 31, 2013	(unfavorable)
	Cross-currency swap	$	1,598		Other long-term assets
	As of December 31, 2012
	Cross-currency swap	$	305		Other long-term assets
Schedule of Gain (Loss) Recognized on Derivative Instruments	'
		Three Months Ended
		March 31,
	(US$ in thousands)	2013			2012
	Cross-currency swap unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	$	(318	)	$	509

Fair_value_measurements_Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis	'
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(US$ in thousands)	Balance		Level 1		Level 2		Level 3
		March 31,
		2013
	Derivative financial instruments
	Cash flow hedges
	Cross-currency swap	$	1,598	$	—	$	1,598	$	—
	(US$ in thousands)	Balance		Level 1		Level 2		Level 3
		December 31,
		2012
	Derivative financial instruments
	Cash flow hedges
	Cross currency swap	$	305	$	—	$	305	$	—

Comprehensive_income_loss_Tabl

Comprehensive income (loss) (Tables)	3 Months Ended
	Mar. 31, 2013
Equity [Abstract]	'
Schedule of Comprehensive Income (Loss)	'
	The components of and changes in accumulated other comprehensive income were as follows:
	(US$ in thousands)		Foreign			Fair Value of			Accumulated
			Currency			Cross-			Other
			Translation			Currency			Comprehensive
			Adjustments			Swap			Income
	Balance at December 31, 2012		$	4,614		$	131		$	4,745
	Unrealized gain on cross-currency swap, net of tax of $187			—			(318	)		(318	)
	Foreign currency translation adjustment (1)			(2,708	)		—			(2,708	)
	Balance at March 31, 2013		$	1,906		$	(187	)	$	1,719
	-1	As the cash generally remains permanently invested in the non-U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share_Tables

Earnings per share (Tables)	3 Months Ended
	Mar. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share	'
	The following is a reconciliation of the weighted average shares used in the basic and diluted net income per common share computations.
		Three Months Ended
		March 31,
		2013		2012
	Weighted average common shares-basic		19,431,093		18,675,694
	Effect of dilutive securities:
	Unexercised stock options net of treasury share repurchase		260,048		440,501
	Weighted average common shares-diluted		19,691,141		19,116,195

Sharebased_compensation_Tables

Share-based compensation (Tables)	3 Months Ended
	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Share-Based Compensation by Line Item in Condensed Consolidated Statements of Operations	'
	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended
		March 31,
	(US$ in thousands)	2013		2012
	Cost of sales	$	287	$	176
	Sales and marketing		436		445
	General and administrative		1,175		770
	Research and development		45		42
	Total	$	1,943	$	1,433

Other_income_expense_Tables

Other income (expense) (Tables)	3 Months Ended
	Mar. 31, 2013
Other Income And Expenses [Abstract]	'
Summary of Other Income (Expense)	'
	The following table shows the detail of other income (expense):
			Three Months Ended
			March 31,
	(US$ in thousands)		2013			2012
			(Restated)			(Restated)
	Gain related to demutualization of a mutual insurance company (1)		$	4,406		$	—
	Transactional foreign currency exchange gains (losses)			623			(470	)
	Other			(265	)		(161	)
	Total		$	4,764		$	(631	)
	-1	In the first quarter of 2013, the Company received $4.4 million of cash related to the demutualization of a mutual insurance company, in which the company was an eligible member to share in such proceeds.

Business_segment_information_T

Business segment information (Tables)	3 Months Ended
	Mar. 31, 2013
Segment Reporting [Abstract]	'
Schedule of External Net Sales by GBU Reporting Segment	'
	The table below presents external net sales by GBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of sales of Trinity Evolution ® in spine and orthopedic applications.
			External Net Sales by GBU
			Three Months Ended March 31,
	(US$ in thousands)		2013			2012			Reported			Constant
									Decline			Currency
												Decline
			(Restated)			(Restated)			(Restated)			(Restated)
	Spine
	Spine Repair Implants and Regenerative Biologics		$	36,280		$	34,393			5	%		0	%
	Spine Regenerative Stimulation			33,744			38,790			(13	)%		(17	)%
	Total Spine			70,024			73,183			(4	)%		(9	)%
	Orthopedics			33,349			35,753			(7	)%		(3	)%
	Total Net Sales		$	103,373		$	108,936			(5	)%		(7	)%
Operating Income (Loss) by GBU	'
	The table below presents operating income (loss) by GBU reporting segment:
	Operating Income (Loss) by GBU		Three Months Ended
			March 31,
	(US$ in thousands)		2013			2012
			(Restated)			(Restated)
	Spine		$	14,680		$	22,019
	Orthopedics			2,041			71
	Corporate (1)			(8,634	)		(4,170	)
	Total		$	8,087		$	17,920
	-1	For the three months ended March 31, 2013, the operating loss for Corporate included $3.6 million of management succession charges.

Sale_of_Breg_and_Disposition_o1

Sale of Breg and Disposition of Sports Medicine GBU (Tables)	3 Months Ended
	Mar. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Schedule of Information Related to Sale of Breg	'
	The following table presents the value of the asset disposition, proceeds received, net of various working capital adjustments and indebtedness and net gain on sale of Breg as shown in the condensed consolidated statement of operations for the year ended December 31, 2012.
	(US$ in thousands)	Total
	Cash proceeds	$	157,500
	Less:
	Working Capital		(7,093	)
	Transaction related expenses		(4,276	)
	Fair Value of Indemnification		(2,000	)
	Tangible assets		(8,309	)
	Intangible assets		(28,164	)
	Goodwill		(106,200	)
	Gain on sale of Breg, before income taxes		1,458
	Income tax expense		(113	)
	Gain on sale of Breg, net of taxes	$	1,345

Restatement_of_the_Condensed_C2

Restatement of the Condensed Consolidated Financial Statements - Additional Information (Detail) (USD $)	3 Months Ended			12 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	Jun. 30, 2012	Dec. 31, 2012
			Distributor Revenue [Member]	Distributor Revenue [Member]	Inventory Reserves [Member]	Inventory Reserves [Member]	Inventory Reserves [Member]
			Distributor
Increase (Decrease) in net sales	$3,100,000	$7,100,000	'	'	'	'	'
Increase (Decrease) in net income from continued operation	2,700,000	-3,600,000	'	'	'	'	'
Distributors that did not meet the fixed or determinable or collectability revenue recognition criteria	'	'	4	'	'	'	'
Number of distributer terminated	'	'	2	'	'	'	'
Sales return	'	'	'	3,300,000	'	'	'
Increase (Decrease) in accounts receivable	-8,589,000	5,423,000	-34,300,000	-41,300,000	'	'	'
Increase (Decease) in inventory	2,100,000	1,510,000	8,800,000	11,000,000	-14,800,000	'	-14,800,000
Increase (Decrease) in inventory reserve	'	'	'	'	'	$1,200,000	'

Restatement_of_the_Condensed_C3

Restatement of the Condensed Consolidated Financial Statements - Adjustments to Previously Filed Consolidated Income Statements (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Net sales	$103,373	$108,936
Cost of sales	25,617	21,378
Gross profit	77,756	87,558
Operating expenses	'	'
Sales and marketing	45,054	47,128
General and administrative	18,330	14,570
Research and development	5,741	7,050
Amortization of intangibles assets	544	580
Charges related to U.S. Government resolutions	'	310
Total operation expenses	69,669	69,638
Operating income	8,087	17,920
Other income and (expense)	4,204	-2,852
Income before income taxes	12,291	15,068
Income tax expense	-4,681	-6,471
Net income from continuing operations, net of tax	7,610	8,597
Previously Reported [Member]	'	'
Net sales	100,254	116,042
Cost of sales	22,699	21,940
Gross profit	77,555	94,102
Operating expenses	'	'
Sales and marketing	48,839	49,521
General and administrative	18,788	14,570
Research and development	5,400	7,050
Amortization of intangibles assets	504	530
Charges related to U.S. Government resolutions	'	'
Total operation expenses	73,531	71,671
Operating income	4,024	22,431
Other income and (expense)	4,204	-2,852
Income before income taxes	8,228	19,579
Income tax expense	-3,320	-7,363
Net income from continuing operations, net of tax	4,908	12,216
Total Adjustments [Member]	'	'
Net sales	3,119	-7,106
Cost of sales	2,918	-562
Gross profit	201	-6,544
Operating expenses	'	'
Sales and marketing	-3,785	-2,393
General and administrative	-458	'
Research and development	341	'
Amortization of intangibles assets	40	50
Charges related to U.S. Government resolutions	'	310
Total operation expenses	-3,862	-2,033
Operating income	4,063	-4,511
Other income and (expense)	'	'
Income before income taxes	4,063	-4,511
Income tax expense	-1,361	892
Net income from continuing operations, net of tax	2,702	-3,619
Distributor Revenue [Member]	'	'
Net sales	2,963	-7,394
Cost of sales	471	-1,471
Gross profit	2,492	-5,923
Operating expenses	'	'
Sales and marketing	-2,073	-417
General and administrative	'	'
Research and development	'	'
Amortization of intangibles assets	'	'
Charges related to U.S. Government resolutions	'	'
Total operation expenses	-2,073	-417
Operating income	4,565	-5,506
Other income and (expense)	'	'
Income before income taxes	4,565	-5,506
Income tax expense	-1,529	1,089
Net income from continuing operations, net of tax	3,036	-4,417
Inventory Reserves [Member]	'	'
Net sales	'	'
Cost of sales	86	-1,212
Gross profit	-86	1,212
Operating expenses	'	'
Sales and marketing	'	'
General and administrative	'	'
Research and development	'	'
Amortization of intangibles assets	'	'
Charges related to U.S. Government resolutions	'	'
Total operation expenses	'	'
Operating income	-86	1,212
Other income and (expense)	'	'
Income before income taxes	-86	1,212
Income tax expense	29	-240
Net income from continuing operations, net of tax	-57	972
Royalties [Member]	'	'
Net sales	'	'
Cost of sales	2,030	2,126
Gross profit	-2,030	-2,126
Operating expenses	'	'
Sales and marketing	-2,030	-2,126
General and administrative	'	'
Research and development	'	'
Amortization of intangibles assets	'	'
Charges related to U.S. Government resolutions	'	'
Total operation expenses	-2,030	-2,126
Operating income	'	'
Other income and (expense)	'	'
Income before income taxes	'	'
Income tax expense	'	'
Net income from continuing operations, net of tax	'	'
Other [Member]	'	'
Net sales	156	288
Cost of sales	331	-5
Gross profit	-175	293
Operating expenses	'	'
Sales and marketing	318	150
General and administrative	-458	'
Research and development	341	'
Amortization of intangibles assets	40	50
Charges related to U.S. Government resolutions	'	310
Total operation expenses	241	510
Operating income	-416	-217
Other income and (expense)	'	'
Income before income taxes	-416	-217
Income tax expense	139	43
Net income from continuing operations, net of tax	($277)	($174)

Restatement_of_the_Condensed_C4

Restatement of the Condensed Consolidated Financial Statements - Effects of Restatement on Condensed Consolidated Balance Sheet (Detail) (USD $)	Mar. 31, 2013		Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets:	'		'	'	'
Cash and cash equivalents	$33,675	[1]	$31,055	$47,053	$33,207
Restricted cash	29,446	[1]	21,314	'	'
Trade accounts receivable, less allowances of $11,731	96,506	[1]	107,312	'	'
Inventories	84,691	[1]	83,373	'	'
Deferred income taxes	33,915	[1]	33,450	'	'
Prepaid expenses and other current assets	34,390	[1]	34,079	'	'
Total current assets	312,623	[1]	310,583	'	'
Property, plant and equipment, net	54,119	[1]	53,835	'	'
Patents and other intangible assets, net	6,935	[1]	7,290	'	'
Goodwill	72,607	[1]	74,388	'	'
Deferred income taxes	19,176	[1]	18,881	'	'
Other long-term assets	10,298	[1]	7,920	'	'
Total assets	475,758	[1]	472,897	'	'
Current liabilities:	'		'	'	'
Trade accounts payable	14,987	[1]	22,575	'	'
Other current liabilities	44,729	[1]	39,610	'	'
Total current liabilities	59,716	[1]	62,185	'	'
Long-term debt	20,000	[1]	20,000	'	'
Deferred income taxes	12,225	[1]	11,456	'	'
Other long-term liabilities	10,425	[1]	11,424	'	'
Total liabilities	102,366	[1]	105,065	'	'
Contingencies (Note 17)	'	[1]	'	'	'
Shareholders' equity:	'		'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	1,945	[1]	1,934	'	'
Additional paid-in capital	250,381	[1]	246,306	'	'
Retained earnings	119,347	[1]	114,847	'	'
Accumulated other comprehensive income	1,719	[1]	4,745	'	'
Total shareholders' equity	373,392	[1]	367,832	'	'
Total liabilities and shareholders' equity	475,758	[1]	472,897	'	'
Previously Reported [Member]	'		'	'	'
Current assets:	'		'	'	'
Cash and cash equivalents	33,675		31,055	'	'
Restricted cash	29,446		21,314	'	'
Trade accounts receivable, less allowances of $11,731	132,425		150,316	'	'
Inventories	92,133		88,744	'	'
Deferred income taxes	17,363		16,959	'	'
Prepaid expenses and other current assets	32,211		32,056	'	'
Total current assets	337,253		340,444	'	'
Property, plant and equipment, net	52,402		51,362	'	'
Patents and other intangible assets, net	6,765		6,880	'	'
Goodwill	72,607		74,388	'	'
Deferred income taxes	20,200		19,904	'	'
Other long-term assets	14,153		11,303	'	'
Total assets	503,380		504,281	'	'
Current liabilities:	'		'	'	'
Trade accounts payable	14,230		21,812	'	'
Other current liabilities	51,295		46,985	'	'
Total current liabilities	65,525		68,797	'	'
Long-term debt	20,000		20,000	'	'
Deferred income taxes	11,460		11,456	'	'
Other long-term liabilities	4,227		4,930	'	'
Total liabilities	101,212		105,183	'	'
Contingencies (Note 17)	'		'	'	'
Shareholders' equity:	'		'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	1,945		1,934	'	'
Additional paid-in capital	250,186		246,111	'	'
Retained earnings	150,665		148,549	'	'
Accumulated other comprehensive income	-628		2,504	'	'
Total shareholders' equity	402,168		399,098	'	'
Total liabilities and shareholders' equity	503,380		504,281	'	'
Adjustments [Member]	'		'	'	'
Current assets:	'		'	'	'
Cash and cash equivalents	'		'	'	'
Restricted cash	'		'	'	'
Trade accounts receivable, less allowances of $11,731	-35,919		-43,004	'	'
Inventories	-7,442		-5,371	'	'
Deferred income taxes	16,552		16,491	'	'
Prepaid expenses and other current assets	2,179		2,023	'	'
Total current assets	-24,630		-29,861	'	'
Property, plant and equipment, net	1,717		2,473	'	'
Patents and other intangible assets, net	170		410	'	'
Goodwill	'		'	'	'
Deferred income taxes	-1,024		-1,023	'	'
Other long-term assets	-3,855		-3,383	'	'
Total assets	-27,622		-31,384	'	'
Current liabilities:	'		'	'	'
Trade accounts payable	757		763	'	'
Other current liabilities	-6,566		-7,375	'	'
Total current liabilities	-5,809		-6,612	'	'
Long-term debt	'		'	'	'
Deferred income taxes	765		'	'	'
Other long-term liabilities	6,198		6,494	'	'
Total liabilities	1,154		-118	'	'
Contingencies (Note 17)	'		'	'	'
Shareholders' equity:	'		'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	'		'	'	'
Additional paid-in capital	195		195	'	'
Retained earnings	-31,318		-33,702	'	'
Accumulated other comprehensive income	2,347		2,241	'	'
Total shareholders' equity	-28,776		-31,266	'	'
Total liabilities and shareholders' equity	($27,622)		($31,384)	'	'
[1]	Unaudited

Restatement_of_the_Condensed_C5

Restatement of the Condensed Consolidated Financial Statements - Effects of Restatement on Condensed Consolidated Balance Sheet (Parenthetical) (Detail) (USD $)	Mar. 31, 2013		Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'		'
Trade accounts receivable, allowances	$11,731	[1]	$13,543
Common shares, par value	$0.10	[1]	$0.10
Common shares, authorized	50,000,000	[1]	50,000,000
Common shares, issued	19,453,294	[1]	19,339,329
Common shares, outstanding	19,453,294	[1]	19,339,329
[1]	Unaudited

Restatement_of_the_Condensed_C6

Restatement of the Condensed Consolidated Financial Statements - Effects of Restatement on Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Product sales	$91,336	$97,608
Marketing service fees	12,037	11,328
Net sales	103,373	108,936
Cost of sales	25,617	21,378
Gross profit	77,756	87,558
Operating expenses	'	'
Sales and marketing	45,054	47,128
General and administrative	18,330	14,570
Research and development	5,741	7,050
Amortization of intangible assets	544	580
Charges related to US Government Resolutions	'	310
Total operating expenses	69,669	69,638
Operating income	8,087	17,920
Other income and expense	'	'
Interest expense, net	-560	-2,221
Other income (expense), net	4,764	-631
Total other income (expense)	4,204	-2,852
Income before income taxes	12,291	15,068
Income tax expense	-4,681	-6,471
Net income from continuing operations, net of tax	7,610	8,597
Discontinued operations (Note 16)	'	'
(Loss) income from discontinued operations	-4,434	527
Income tax benefit	1,324	283
Net (loss) income from discontinued operations, net of tax	-3,110	810
Net income	4,500	9,407
Net income (loss) per common share- basic:	'	'
Net income from continuing operations, net of tax	$0.39	$0.46
Net (loss) income from discontinued operations, net of tax	($0.16)	$0.04
Net income per common share- basic	$0.23	$0.50
Net income (loss) per common share- diluted:	'	'
Net income from continuing operations, net of tax	$0.39	$0.45
Net (loss) income from discontinued operations, net of tax	($0.16)	$0.04
Net income per common share- diluted	$0.23	$0.49
Weighted average number of common shares:	'	'
Basic	19,431,093	18,675,694
Diluted	19,691,141	19,116,195
Comprehensive (loss) income	1,474	11,808
Previously Reported [Member]	'	'
Product sales	88,358	104,820
Marketing service fees	11,896	11,222
Net sales	100,254	116,042
Cost of sales	22,699	21,940
Gross profit	77,555	94,102
Operating expenses	'	'
Sales and marketing	48,839	49,521
General and administrative	18,788	14,570
Research and development	5,400	7,050
Amortization of intangible assets	504	530
Charges related to US Government Resolutions	'	'
Total operating expenses	73,531	71,671
Operating income	4,024	22,431
Other income and expense	'	'
Interest expense, net	-560	-2,221
Other income (expense), net	4,764	-631
Total other income (expense)	4,204	-2,852
Income before income taxes	8,228	19,579
Income tax expense	-3,320	-7,363
Net income from continuing operations, net of tax	4,908	12,216
Discontinued operations (Note 16)	'	'
(Loss) income from discontinued operations	-4,432	-506
Income tax benefit	1,640	306
Net (loss) income from discontinued operations, net of tax	-2,792	-200
Net income	2,116	12,016
Net income (loss) per common share- basic:	'	'
Net income from continuing operations, net of tax	$0.25	$0.65
Net (loss) income from discontinued operations, net of tax	($0.14)	($0.01)
Net income per common share- basic	$0.11	$0.64
Net income (loss) per common share- diluted:	'	'
Net income from continuing operations, net of tax	$0.25	$0.64
Net (loss) income from discontinued operations, net of tax	($0.14)	($0.01)
Net income per common share- diluted	$0.11	$0.63
Weighted average number of common shares:	'	'
Basic	19,431,093	18,675,694
Diluted	19,691,141	19,116,195
Comprehensive (loss) income	-1,016	14,726
Adjustments [Member]	'	'
Product sales	2,978	-7,212
Marketing service fees	141	106
Net sales	3,119	-7,106
Cost of sales	2,918	-562
Gross profit	201	-6,544
Operating expenses	'	'
Sales and marketing	-3,785	-2,393
General and administrative	-458	'
Research and development	341	'
Amortization of intangible assets	40	50
Charges related to US Government Resolutions	'	310
Total operating expenses	-3,862	-2,033
Operating income	4,063	-4,511
Other income and expense	'	'
Income before income taxes	4,063	-4,511
Income tax expense	-1,361	892
Net income from continuing operations, net of tax	2,702	-3,619
Discontinued operations (Note 16)	'	'
(Loss) income from discontinued operations	-2	1,033
Income tax benefit	-316	-23
Net (loss) income from discontinued operations, net of tax	-318	1,010
Net income	2,384	-2,609
Net income (loss) per common share- basic:	'	'
Net income from continuing operations, net of tax	$0.14	($0.19)
Net (loss) income from discontinued operations, net of tax	($0.02)	$0.05
Net income per common share- basic	$0.12	($0.14)
Net income (loss) per common share- diluted:	'	'
Net income from continuing operations, net of tax	$0.14	($0.19)
Net (loss) income from discontinued operations, net of tax	($0.02)	$0.05
Net income per common share- diluted	$0.12	($0.14)
Weighted average number of common shares:	'	'
Basic	'	'
Diluted	'	'
Comprehensive (loss) income	$2,490	($2,918)

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Mar. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'		'
Raw materials	$5,847		$7,623
Work-in-process	7,401		7,886
Finished products	33,234		28,308
Field inventory	22,963		22,629
Consignment inventory	5,765		6,155
Deferred cost of sales	9,481		10,772
Total Inventory	$84,691	[1]	$83,373
[1]	Unaudited

Patents_and_other_intangible_a2

Patents and other intangible assets - Schedule of Patents and Other Intangibles Assets (Detail) (USD $)	Mar. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Finite And Indefinite Lived Intangible Assets [Line Items]	'		'
Cost	$39,679		$39,562
Accumulated amortization	-32,744		-32,272
Patents and other intangible assets, net	6,935	[1]	7,290
Patents [Member]	'		'
Finite And Indefinite Lived Intangible Assets [Line Items]	'		'
Cost	39,000		38,905
Accumulated amortization	-32,292		-31,845
Trademarks - definite lived [Member]	'		'
Finite And Indefinite Lived Intangible Assets [Line Items]	'		'
Cost	679		657
Accumulated amortization	($452)		($427)
[1]	Unaudited

Goodwill_Schedule_of_Changes_i

Goodwill - Schedule of Changes in Net Carrying Amount of Goodwill (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Beginning balance	$74,388
Foreign currency	-1,781
Ending balance	$72,607	[1]
[1]	Unaudited

Bank_borrowings_Additional_Inf

Bank borrowings - Additional Information (Detail)	Mar. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
In Millions, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Debt Disclosure [Abstract]	'	'	'	'
Amount outstanding under lines of credit	$0	'	$0.10	'
Weighted average interest rate on borrowings under lines of credit	'	'	3.70%	3.70%
Maximum borrowing capacity	$7.40	€ 5.80	$7.60	€ 5.80

Longterm_debt_Additional_Infor

Long-term debt - Additional Information (Detail)

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2012

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

31-May-12

Aug. 31, 2010

Mar. 31, 2013

Dec. 31, 2012

Aug. 30, 2010

Mar. 31, 2013

Dec. 31, 2012

31-May-12

Aug. 31, 2010

Mar. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Aug. 31, 2010

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

New Credit Agreement [Member]

New Credit Agreement [Member]

New Credit Agreement [Member]

Prior Credit Agreement [Member]

Prior Credit Agreement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

LIBOR [Member]

LIBOR [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Base rate [Member]

USD ($)

LIBOR [Member]

Base rate [Member]

LIBOR [Member]

LIBOR [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument term (in years)

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

$7,400,000

€ 5,800,000

$7,600,000

€ 5,800,000

'

'

'

'

'

'

$200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

Maximum additional borrowing capacity available

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

Repayment of debt obligation

3,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

87,500,000

'

'

'

'

'

'

'

'

'

Repayment of debt obligation

'

'

'

'

'

20,000,000

20,000,000

57,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding

'

0

'

100,000

'

'

'

'

'

20,000,000

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Margin on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

2.50%

'

'

'

'

'

'

3.25%

2.25%

'

'

Variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'LIBOR

'

'

'

'

'

Effective interest rate (as a Percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.70%

2.70%

Revolving credit facility due date

'

'

'

'

'

'

'

'

'

30-Aug-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of restricted net assets

'

225,200,000

'

213,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

29,446,000

[1]

'

21,314,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

Write-off of debt issue costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

'

'

'

'

Deferred debt issuance costs, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,600,000

$1,800,000

'

'

'

'

'

'

[1]

Unaudited

Derivative_instruments_Schedul

Derivative instruments - Schedule of Fair Values of Derivative Instruments (Detail) (Other long-term assets [Member], Cross-currency swap [Member], USD $)	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other long-term assets [Member] | Cross-currency swap [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value: favorable (unfavorable)	$1,598	$305

Derivative_instruments_Schedul1

Derivative instruments - Schedule of Gain (Loss) Recognized on Derivative Instruments (Detail) (Cross-currency swap [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Cross-currency swap [Member]	'	'
Derivative Instruments [Line Items]	'	'
Cross-currency swap unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	($318)	$509

Derivative_instruments_Additio

Derivative instruments - Additional Information (Detail)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2010	Sep. 30, 2010
	Swap Agreement [Member]	Cross-currency swap [Member]	Cross-currency swap [Member]
		Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]
		Pay Euros [Member]	Receive U.S. dollars [Member]
		EUR (€)	USD ($)
Derivatives, Fair Value [Line Items]	'	'	'
Notional amount	'	€ 28.70	$39
Fixed rate (as a percent)	'	5.00%	4.64%
Swap agreement expiration date	30-Dec-16	'	'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (Maximum [Member])	3 Months Ended
	Mar. 31, 2013
Maximum [Member]	'
Financial Instruments And Fair Value Measurements [Line Items]	'
Cash Equivalents Original Maturity Period	'90 days

Fair_value_measurements_Schedu

Fair value measurements - Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cross currency swap	$1,598	$305
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cross currency swap	$1,598	$305

Comprehensive_income_loss_Sche

Comprehensive income (loss) - Schedule of Comprehensive Income (Loss) (Detail) (USD $)	Mar. 31, 2013		Dec. 31, 2012	Mar. 31, 2013	Mar. 31, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified				Foreign Currency Translation Adjustments [Member]	Fair Value of Cross- Currency Swaps [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]	'		'	'	'	'
Beginning balance	$1,719	[1]	$4,745	$4,614	$131	$4,745
Unrealized gain on cross-currency swap, net of tax	'		'	'	-318	-318
Foreign currency translation adjustment	'		'	-2,708	'	-2,708
Ending balance	$1,719	[1]	$4,745	$1,906	($187)	$1,719
[1]	Unaudited

Comprehensive_income_loss_Sche1

Comprehensive income (loss) - Schedule of Comprehensive Income (Loss) (Parenthetical) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'
Deferred taxes recognized on related foreign currency translation adjustment	$0
Accumulated Other Comprehensive Income (Loss) [Member]	'
Accumulated Other Comprehensive Income Loss [Line Items]	'
Unrealized gain on derivative instrument, taxes	$187

Earnings_per_share_Schedule_of

Earnings per share - Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Earnings Per Share [Abstract]	'	'
Weighted average common shares-basic	19,431,093	18,675,694
Effect of dilutive securities:	'	'
Unexercised stock options net of treasury share repurchase	260,048	440,501
Weighted average common shares-diluted	19,691,141	19,116,195

Earnings_per_share_Additional_

Earnings per share - Additional Information (Detail) (Options to purchase common stock [Member])	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Options to purchase common stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding options not included in diluted earnings per share	973,037	714,686

Sharebased_compensation_Schedu

Share-based compensation - Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share based compensation expense	$1,943	$1,433
Cost of sales [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share based compensation expense	287	176
Sales and marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share based compensation expense	436	445
General and administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share based compensation expense	1,175	770
Research and development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share based compensation expense	$45	$42

Share_based_compensation_Addit

Share based compensation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Common stock issued under Employee Stock Purchase Plan (in shares)	113,965	262,713

Other_Income_Expense_Summary_o

Other Income (Expense) - Summary of Other Income (Expenses) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Other Income And Expenses [Abstract]	'	'
Gain related to demutualization of a mutual insurance company	$4,406	'
Transactional foreign currency exchange gains (losses)	623	-470
Other	-265	-161
Total	$4,764	($631)

Other_Income_Expense_Summary_o1

Other Income (Expense) - Summary of Other Income (Expenses) (Parenthetical) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Other Income And Expenses [Abstract]	'
Cash related to demutualization	$4.40

Income_taxes_Additional_Inform

Income taxes - Additional Information (Detail) (USD $)	3 Months Ended					12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012
				Minimum [Member]	Maximum [Member]	Maximum [Member]
						U S Subsidiaries [Member]
Income Tax [Line Items]	'	'	'	'	'	'
Provision for income tax	$4,681,000	$6,471,000	'	'	'	'
Income tax effective rate (as a percent)	38.10%	42.90%	'	'	'	'
Income tax effective rate excluding the impact of the charges related to the U.S. Government resolutions (as a percent)	38.10%	39.50%	'	'	'	'
Gross unrecognized tax benefit	800,000	'	1,200,000	'	'	'
Accrued interest and penalties related to unrecognized tax benefits	900,000	'	900,000	'	'	'
Unremitted foreign earnings	'	'	'	285,300,000	'	'
Unremitted foreign earnings	'	'	'	'	292,000,000	'
Amount of earnings in US subsidiaries	'	'	'	'	'	$293,800,000

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013
	Segment
Segment Reporting [Abstract]	'
Number of global business units	2

Business_segment_information_S

Business segment information - Schedule of External Net Sales by GBU Reporting Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Segment Reporting Information [Line Items]	'	'
Reported Decline (as a percent)	-5.00%	'
Constant Currency Decline (as a percent)	-7.00%	'
Total Net Sales	$103,373	$108,936
Spine Repair Implants and Regenerative Biologics [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Reported Decline (as a percent)	5.00%	'
Constant Currency Decline (as a percent)	0.00%	'
Total Net Sales	36,280	34,393
Spine Regenerative Stimulation [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Reported Decline (as a percent)	-13.00%	'
Constant Currency Decline (as a percent)	-17.00%	'
Total Net Sales	33,744	38,790
Spine [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Reported Decline (as a percent)	-4.00%	'
Constant Currency Decline (as a percent)	-9.00%	'
Total Net Sales	70,024	73,183
Orthopedics [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Reported Decline (as a percent)	-7.00%	'
Constant Currency Decline (as a percent)	-3.00%	'
Total Net Sales	$33,349	$35,753

Business_segment_information_O

Business segment information - Operating Income (Loss) by GBU (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Product Type Reporting Information [Line Items]	'	'
Operating Income (Loss) by GBU	$8,087	$17,920
Spine [Member]	'	'
Product Type Reporting Information [Line Items]	'	'
Operating Income (Loss) by GBU	14,680	22,019
Orthopedics [Member]	'	'
Product Type Reporting Information [Line Items]	'	'
Operating Income (Loss) by GBU	2,041	71
Corporate [Member]	'	'
Product Type Reporting Information [Line Items]	'	'
Operating Income (Loss) by GBU	($8,634)	($4,170)

Business_segment_information_O1

Business segment information - Operating Income (Loss) by GBU (Parenthetical) (Detail) (Corporate [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Corporate [Member]	'
Product Type Reporting Information [Line Items]	'
Senior management succession charges	$3.60

Sale_of_Breg_and_Disposition_o2

Sale of Breg and Disposition of Sports Medicine GBU - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	24-May-12	Mar. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Indemnification Expense	'	$4,000,000	'
Breg Orthofix Holdings, Inc [Member]	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Obligations under guarantee	'	'	2,000,000
Orthofix Inc [Member] | Breg Orthofix Holdings, Inc [Member]	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Proceeds from sale of outstanding shares of Breg	157,500,000	'	'
Prepayment of outstanding company indebtedness	145,000,000	'	'
Fair value of liability	2,000,000	'	'
Period of indemnification (in years)	'	'3 years	'
Obligations under guarantee	'	$1,400,000	$1,600,000

Sale_of_Breg_and_Disposition_o3

Sale of Breg and Disposition of Sports Medicine GBU - Schedule of Information Related to Sale of Breg (Detail) (Breg Orthofix Holdings, Inc [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Breg Orthofix Holdings, Inc [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Cash proceeds	$157,500
Less:	'
Working Capital	-7,093
Transaction related expenses	-4,276
Fair Value of Indemnification	-2,000
Tangible assets	-8,309
Intangible assets	-28,164
Goodwill	-106,200
Gain on sale of Breg, before income taxes	1,458
Income tax expense	-113
Gain on sale of Breg, net of taxes	$1,345

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], USD $)	0 Months Ended	3 Months Ended
In Millions, unless otherwise specified	8-May-13	Sep. 30, 2013	Jun. 30, 2013
Subsequent Event [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Share repurchase program, authorized amount	$50	'	'
Stock repurchased value	'	$39.50	$39.50